This was posted on YMB by PU83jw about 4 hours ago
ALERT -- I have two long-standing college friends who are in Senior Mgmt. at both Pfizer and Merck. Today with Merck's announcement that they will be discontinuing the advancement/development of their COVID-19 vaccine MRK-7110, I thought I'd put a call into both of them to get their current thoughts on EUAs / FDA and Vaccines vs. Therapy alternatives. To my surprise, both friends were very aware of CYDY (more specifically Leronlimab) its EUA struggles, and some of the very positive recent results. In both conversations, I was able to confirm there are "current" conversations between their respective firms and CYDY. Additionally, both apologized that for "security reasons" they really couldn't comment on the nature of the discussions but assured me things appear very positive (emphasis added) for CYDY's future. I tried hard for both of them to "clarify" their statements, but both were getting uncomfortable with going any further with respect to the topic of Leronlimab. The one comment given to me (without any details) before the end of one of the calls was "hold on to your CYDY shares." You can interpret that in many ways. Thought I'd pass this along to this Board given there are so many folks here working so hard to get Leronlimab released to the larger, struggling therapeutics market.
Of course a lot of commenters think it is bogus. The OP did respond to some of the comments and his history does not include many posts on the CYDY board. His last post there before today was 8 days ago.
The last CC did include a vague reference to conversations with majors (don't remember exactly how it was phrased). Also, the article linked below has the following:
Merck has disclosed more setbacks to its COVID-19 strategy. Having already pulled out of vaccines, Merck has now stopped developing one medicine in hospitalized patients and given up completely on another drug in COVID-19.
https://www.fiercebiotech.com/biotech/merck-c...id=3247597
ALERT -- I have two long-standing college friends who are in Senior Mgmt. at both Pfizer and Merck. Today with Merck's announcement that they will be discontinuing the advancement/development of their COVID-19 vaccine MRK-7110, I thought I'd put a call into both of them to get their current thoughts on EUAs / FDA and Vaccines vs. Therapy alternatives. To my surprise, both friends were very aware of CYDY (more specifically Leronlimab) its EUA struggles, and some of the very positive recent results. In both conversations, I was able to confirm there are "current" conversations between their respective firms and CYDY. Additionally, both apologized that for "security reasons" they really couldn't comment on the nature of the discussions but assured me things appear very positive (emphasis added) for CYDY's future. I tried hard for both of them to "clarify" their statements, but both were getting uncomfortable with going any further with respect to the topic of Leronlimab. The one comment given to me (without any details) before the end of one of the calls was "hold on to your CYDY shares." You can interpret that in many ways. Thought I'd pass this along to this Board given there are so many folks here working so hard to get Leronlimab released to the larger, struggling therapeutics market.
Of course a lot of commenters think it is bogus. The OP did respond to some of the comments and his history does not include many posts on the CYDY board. His last post there before today was 8 days ago.
The last CC did include a vague reference to conversations with majors (don't remember exactly how it was phrased). Also, the article linked below has the following:
Merck has disclosed more setbacks to its COVID-19 strategy. Having already pulled out of vaccines, Merck has now stopped developing one medicine in hospitalized patients and given up completely on another drug in COVID-19.
https://www.fiercebiotech.com/biotech/merck-c...id=3247597
5
